Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaxneuvance vs Prevnar 13 in Adults 50+ (PNEU-AGE)
NCT03950622Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With a Solicited Injection-site Adverse Event at Day 5, Percentage of Participants With Solicited Systemic Adverse Events at Day 14 and 3 more. Started Jun 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03950622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950622.